Predictors of treatment satisfaction in antipsychotic-naïve and previously medicated patients with acute-phase psychosis

References

• Valenstein M, Mitchinson A, Ronis DL, et al. Quality indicators and monitoring of mental health services: what do frontline providers think? Am J Psychiatry. 2004;161:146–153.
   PubMed Web of Science ®Google Scholar
• Chue P. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol. 2006;20:38–56.
   PubMedGoogle Scholar
• Ruggeri M, Nosè M, Bonetto C, et al. Changes and predictors of change in objective and subjective quality of life: multiwave follow-up study in community psychiatric practice. Br J Psychiatry. 2005;187:121–130.
   PubMed Web of Science ®Google Scholar
• Vermeulen JM, Schirmbeck NF, van Tricht MJ, et al. Satisfaction of psychotic patients with care and its value to predict outcomes. Eur Psychiatry. 2018;47:60–66.
   PubMed Web of Science ®Google Scholar
• Eiring O, Landmark BF, Aas E, et al. What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. BMJ Open. 2015;5:e007848.
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Kissling W. Psychoeducation for patients with schizophrenia and their families. Expert Rev Neurother. 2008;8:1067–1077.
   PubMedGoogle Scholar
• Gebhardt S, Wolak AM, Huber MT. Patient satisfaction and clinical parameters in psychiatric inpatients – the prevailing role of symptom severity and pharmacologic disturbances. Compr Psychiatry. 2013;54:53–60.
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Greenspan A, Rupnow MF, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Stroup S, Keefe RSE, et al. Measuring outcome priorities and preferences in people with schizophrenia. Br J Psychiatry. 2005;187:529–536.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4:694.
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–942.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–378.
   PubMed Web of Science ®Google Scholar
• Miller BJ. A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008;14:289–300.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Dam J. Insight in schizophrenia: a review. Nord J Psychiatry. 2006;60:114–120.
   PubMed Web of Science ®Google Scholar
• Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000;157:1379–1389.
   PubMed Web of Science ®Google Scholar
• Murri MB, Amore M, Calcagno P, et al. The “insight paradox” in schizophrenia: magnitude, moderators and mediators of the association between insight and depression. Schizophr Bull. 2016;42:1225–1233.
   PubMed Web of Science ®Google Scholar
• Murri MB, Respino M, Innamorati M, et al. Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis. Schizophr Res. 2015;162:234–247.
   PubMed Web of Science ®Google Scholar
• Lysaker PH, Pattison ML, Leonhardt BL, et al. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018;17:12–23.
   PubMed Web of Science ®Google Scholar
• Cotton SM, Lambert M, Schimmelmann BG, et al. Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophr Res. 2012;134:20–26.
   PubMed Web of Science ®Google Scholar
• Parellada M, Boada L, Fraguas D, et al. Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal study. Schizophr Bull. 2011;37:38–51.
   PubMed Web of Science ®Google Scholar
• Riedel M, Mayr A, Seemuller F, et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J Biol Psychiatry. 2012;13:30–38.
   PubMed Web of Science ®Google Scholar
• Bo B, Ottesen OH, Gjestad R, et al. Patient satisfaction after acute admission for psychosis. Nord J Psychiatry. 2016;70:321–328.
   PubMed Web of Science ®Google Scholar
• Johnsen E, Kroken RA, Wentzel-Larsen T, et al. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry. 2010;10:26.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer J-P. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 1988;23:99–110.
   PubMed Web of Science ®Google Scholar
• Kjelby E, Sinkeviciute I, Gjestad R, et al. Suicidality in schizophrenia spectrum disorders: the relationship to hallucinations and persecutory delusions. Eur Psychiatry. 2015;30:830–836.
   PubMed Web of Science ®Google Scholar
• Sanz M, Constable G, Lopez-Ibor I, et al. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med. 1998;28:437–446.
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247–251.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: update 2015 Management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16:142–170.
   PubMed Web of Science ®Google Scholar
• Lako IM, Bruggeman R, Knegtering H, et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord. 2012;140:38–47.
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201–208.
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55:5–69.
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;76:1–100.
   PubMed Web of Science ®Google Scholar
• Ahlfors UG, Lewander T, Lindstrom E, et al. Assessment of patient satisfaction with psychiatric care. Development and clinical evaluation of a brief consumer satisfaction rating scale (UKU-ConSat). Nord J Psychiatry. 2001;55:71–90.
   PubMed Web of Science ®Google Scholar
• Malm U, Lewander T. Consumer satisfaction in schizophrenia – a 2-year randomized controlled study of two community-based treatment programs. Nord J Psychiatry. 2001;55:91–96.
   PubMed Web of Science ®Google Scholar
• IBM. IBM SPSS Statistics for Windows Version 23. New York: IBM; 2016.
   Google Scholar
• Muthén LK, Muthén BO. Mplus 7.4 ed. Los Angeles, CA: Muthén & Muthén; 2017.
   Google Scholar
• Wang J, Wang X. Structural equation modeling: applications using Mplus. West Sussex: Wiley; 2012.
   Google Scholar
• Raykov T. On estimating true change interrelationships with other variables. Qual Quant. 1993;27:353–370.
   Web of Science ®Google Scholar
• Kline RB. Principles and practice of structural equation modeling. 3rd ed. New York: Guilford Press; 2011.
   Google Scholar
• Bianchini O, Porcelli S, Nespeca C, et al. Effects of antipsychotic drugs on insight in schizophrenia. Psychiatry Res. 2014;218:20–24.
   PubMed Web of Science ®Google Scholar
• Pijnenborg GHM, Timmerman ME, Derks EM, et al. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European First-Episode Schizophrenia Trial (EUFEST). Eur Neuropsychopharmacol. 2015;25:808–816.
   PubMed Web of Science ®Google Scholar
• Mattila T, Koeter M, Wohlfarth T, et al. The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials. Eur Neuropsychopharmacol. 2017;27:82–86.
   PubMed Web of Science ®Google Scholar
• Mintz AR, Dobson KS, Romney DM. Insight in schizophrenia: a meta-analysis. Schizophr Res. 2003;61:75–88.
   PubMed Web of Science ®Google Scholar
• Sandhu A, Ives J, Birchwood M, et al. The subjective experience and phenomenology of depression following first episode psychosis: a qualitative study using photo-elicitation. J Affect Disord. 2013;149:166–174.
   PubMed Web of Science ®Google Scholar
• Upthegrove R. Depression in schizophrenia and early psychosis: implications for assessment and treatment. Adv Psychiatric Treat. 2009;15:372–379.
   Google Scholar
• Owens DG, Johnstone EC. Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context. Psychol Med. 2006;36:1501–1514.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017;43:240–244.
   PubMed Web of Science ®Google Scholar
• Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of Schizophrenia. Arch Gen Psychiatry. 1990;47:228–236.
   PubMed Web of Science ®Google Scholar
• Austin SF. Promoting well-being in psychosis. Nord J Psychiatry. 2018;72:437–441.
   PubMed Web of Science ®Google Scholar
• Ivarsson B, Malm U. Self-reported consumer satisfaction in mental health services: validation of a self-rating version of the UKU-Consumer Satisfaction Rating Scale. Nord J Psychiatry. 2007;61:194–200.
   PubMed Web of Science ®Google Scholar
• Norlander T, Andersson I, Andersson J, et al. Consumer Satisfaction Rating Scale: revised for use in both psychiatric care and social services. Soc Behav Personal. 2016;44:931–942.
   Web of Science ®Google Scholar